Long-term SGLT2 inhibitor therapy improves myocardial strain and diastolic function in HFpEF: a retrospective study linking functional recovery to reduced myocardial fibrosis - Takeaways - MDSpire

SGLT2 Inhibitor Therapy Enhances Myocardial Strain and Diastolic Function in Patients with HFpEF: A Retrospective Analysis Linking Functional Improvement to Decreased Myocardial Fibrosis

  • By

  • Xiaojin Xu

  • Hongyang Liu

  • Runyang Chen

  • July 21, 2026

Share

  • 1

    SGLT2 inhibitors (SGLT2i) significantly improve left ventricular global longitudinal strain (GLS) in patients with heart failure with preserved ejection fraction (HFpEF).

  • 2

    After 6 months of SGLT2i treatment, NT-proBNP and PⅢNP levels decreased significantly, indicating reduced myocardial fibrosis in HFpEF patients.

  • 3

    The heart failure rehospitalization rate was significantly lower in the SGLT2i group compared to the control group, suggesting improved clinical outcomes.

  • 4

    Multivariate regression analysis identified SGLT2i treatment as an independent predictor of GLS improvement in patients with HFpEF.

  • 5

    The study highlights a potential link between SGLT2i treatment, improved diastolic function, and decreased myocardial fibrosis markers in HFpEF.

Original Source(s)

Long-term SGLT2 inhibitor therapy improves myocardial strain and diastolic function in HFpEF: a retrospective study linking functional recovery to reduced myocardial fibrosis

  • by Xiaojin Xu, Hongyang Liu, Runyang Chen

  • July 21, 2026

Related Content

Multidimensional cardiac functional phenotyping beyond ejection fraction: a multimodality imaging framework for cardiovascular care

Exercise rejuvenates the “muscle-heart” crosstalk: skeletal muscle-derived exosomal miRNAs in cardiac aging

Predictive value of the serum sodium to log(D-dimer) ratio for the risk of all-cause death in patients with chronic heart failure with different ejection fractions